WO2002081621A3 - Vaccin contre le virus de la fievre du nil - Google Patents
Vaccin contre le virus de la fievre du nil Download PDFInfo
- Publication number
- WO2002081621A3 WO2002081621A3 PCT/FR2002/001200 FR0201200W WO02081621A3 WO 2002081621 A3 WO2002081621 A3 WO 2002081621A3 FR 0201200 W FR0201200 W FR 0201200W WO 02081621 A3 WO02081621 A3 WO 02081621A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression vectors
- virus
- fever virus
- nile fever
- vivo
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 206010037660 Pyrexia Diseases 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 abstract 3
- 238000001727 in vivo Methods 0.000 abstract 3
- 108010052285 Membrane Proteins Proteins 0.000 abstract 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 2
- 239000000470 constituent Substances 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000283086 Equidae Species 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 229940031348 multivalent vaccine Drugs 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229940031626 subunit vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2448796A CA2448796C (fr) | 2001-04-06 | 2002-04-05 | Vaccin contre la fievre du nil |
EP15162832.8A EP2979705B1 (fr) | 2001-04-06 | 2002-04-05 | Vaccin contre le virus de la fièvre du nil |
DK02759818.4T DK1377660T3 (en) | 2001-04-06 | 2002-04-05 | Vaccine against nilfeb ervirus |
MXPA03008998A MXPA03008998A (es) | 2001-04-06 | 2002-04-05 | Vacuna contra el virus de la fiebre del nilo. |
ES02759818.4T ES2566044T3 (es) | 2001-04-06 | 2002-04-05 | Vacuna contra el virus de la fiebre del Nilo |
SI200231069A SI1377660T1 (sl) | 2001-04-06 | 2002-04-05 | Cepivo proti virusu Zahodnega Nila |
EP02759818.4A EP1377660B1 (fr) | 2001-04-06 | 2002-04-05 | Vaccin contre le virus de la fievre du nil |
HU0401868A HU230122B1 (hu) | 2001-04-06 | 2002-04-05 | Rekombináns vakcina West Nile vírus ellen |
AU2002307971A AU2002307971B2 (en) | 2001-04-06 | 2002-04-05 | Vaccine against the nile fever virus |
BRPI0208896A BRPI0208896B1 (pt) | 2001-04-06 | 2002-04-05 | vacina contra o vírus da febre do nilo |
PL365210A PL207584B1 (pl) | 2001-04-06 | 2002-04-05 | Szczepionka do ochrony koni, psów, kotów, bydła, świń oraz ptaków przed wirusem zachodniego Nilu (WN) |
IL15820402A IL158204A0 (en) | 2001-04-06 | 2002-04-05 | Vaccine against the nile fever virus |
JP2002579985A JP4426761B2 (ja) | 2001-04-06 | 2002-04-05 | ウエストナイル熱ウイルスに対するワクチン |
ZA2003/07620A ZA200307620B (en) | 2001-04-06 | 2003-09-30 | Vaccine against the nile fever virus |
IL158204A IL158204A (en) | 2001-04-06 | 2003-10-01 | Nile Fever Vaccine |
US10/679,520 US20050031641A1 (en) | 2001-04-06 | 2003-10-06 | Recombinant vaccine against West Nile Virus |
US10/714,781 US7740863B2 (en) | 2001-04-06 | 2003-11-17 | Recombinant vaccine against West Nile Virus |
HK04104755.3A HK1061868A1 (zh) | 2001-04-06 | 2004-07-02 | 對抗尼羅熱病毒的疫苗 |
IL185263A IL185263A0 (en) | 2001-04-06 | 2007-08-14 | Vaccine against the nile fever virus |
US12/758,500 US8535682B2 (en) | 2001-04-06 | 2010-04-12 | Recombinant vaccine against West Nile Virus |
FR16C0014C FR16C0014I2 (fr) | 2001-04-06 | 2016-04-19 | Vaccin contre le virus de la fievre du nil |
LTPA2016011C LTC1377660I2 (lt) | 2001-04-06 | 2016-04-20 | Vakcina nuo Nilo karštligės viruso |
NL300806C NL300806I2 (fr) | 2001-04-06 | 2016-04-20 | |
BE2016C021C BE2016C021I2 (fr) | 2001-04-06 | 2016-04-26 | |
LU93048C LU93048I2 (fr) | 2001-04-06 | 2016-04-26 | Proteq west nile |
CY2016018C CY2016018I2 (el) | 2001-04-06 | 2016-05-20 | Εμβολιο κατα του ιου του δυτικου νειλου |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/04737 | 2001-04-06 | ||
FR0104737A FR2823222B1 (fr) | 2001-04-06 | 2001-04-06 | Vaccin contre le virus de la fievre du nil |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15162832.8A Previously-Filed-Application EP2979705B1 (fr) | 2001-04-06 | 2002-04-05 | Vaccin contre le virus de la fièvre du nil |
US10/374,953 Continuation-In-Part US20040037848A1 (en) | 2001-04-06 | 2003-02-26 | Recombinant vaccine against West Nile Virus |
US10/679,520 Continuation-In-Part US20050031641A1 (en) | 2001-04-06 | 2003-10-06 | Recombinant vaccine against West Nile Virus |
US10/714,781 Continuation-In-Part US7740863B2 (en) | 2001-04-06 | 2003-11-17 | Recombinant vaccine against West Nile Virus |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002081621A2 WO2002081621A2 (fr) | 2002-10-17 |
WO2002081621A3 true WO2002081621A3 (fr) | 2003-02-20 |
Family
ID=8862055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/001200 WO2002081621A2 (fr) | 2001-04-06 | 2002-04-05 | Vaccin contre le virus de la fievre du nil |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1377660B1 (fr) |
JP (1) | JP4426761B2 (fr) |
AU (1) | AU2002307971B2 (fr) |
BE (1) | BE2016C021I2 (fr) |
BR (1) | BRPI0208896B1 (fr) |
CA (1) | CA2448796C (fr) |
CY (2) | CY1117676T1 (fr) |
DK (1) | DK1377660T3 (fr) |
ES (2) | ES2566044T3 (fr) |
FR (2) | FR2823222B1 (fr) |
HK (2) | HK1061868A1 (fr) |
HU (2) | HU230122B1 (fr) |
IL (3) | IL158204A0 (fr) |
LT (1) | LTC1377660I2 (fr) |
LU (1) | LU93048I2 (fr) |
MX (1) | MXPA03008998A (fr) |
NL (1) | NL300806I2 (fr) |
PL (2) | PL207584B1 (fr) |
RU (1) | RU2283138C2 (fr) |
SI (1) | SI1377660T1 (fr) |
WO (1) | WO2002081621A2 (fr) |
ZA (1) | ZA200307620B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004521867A (ja) | 2000-10-27 | 2004-07-22 | イミュノ−アールエックス, インコーポレイテッド | 免疫抑制された患者のためのワクチン免疫療法 |
MXPA04000680A (es) | 2001-07-27 | 2004-04-05 | Wyeth Corp | Vacuna para virus west nile. |
AU2003296974A1 (en) * | 2002-12-13 | 2004-07-14 | Aventis Pasteur, Inc. | Production of alvac on avian embryonic stem cells |
WO2004112694A2 (fr) | 2003-05-23 | 2004-12-29 | Chiron Corporation | Reactifs immunogenes provenant du virus du nil occidental |
CA2582534A1 (fr) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Variants de flavivirus ayant une variation phenotypique et les compositions immunogeniques correspondantes |
PT2251034T (pt) | 2005-12-02 | 2018-05-22 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
MX2011002071A (es) | 2008-08-29 | 2011-04-05 | Boehringer Ingelheim Vetmed | Vacuna para el virus del nilo occidental. |
WO2010091262A1 (fr) | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Virus chimériques de la maladie de newcastle et leurs utilisations |
EP2411049B1 (fr) | 2009-03-27 | 2020-01-15 | Academia Sinica | Procédés et compositions pour l'immunisation contre un virus |
AU2010248761B2 (en) * | 2009-05-15 | 2016-02-11 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
TWI537385B (zh) | 2010-11-04 | 2016-06-11 | 中央研究院 | 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法 |
RU2506093C1 (ru) * | 2012-12-06 | 2014-02-10 | Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук | Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания |
BR112015021414B1 (pt) | 2013-03-14 | 2020-11-10 | Icahn School Of Medicine At Mount Sinai | vírus da doença newcastle e seus usos |
WO2015127501A1 (fr) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Thérapie combinée pour le traitement du cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012128A2 (fr) * | 1998-08-28 | 2000-03-09 | Hawaii Biotechnology Group, Inc. | Vaccin a sous-unite proteique non structurale recombinante contre les infections a flavivirus |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
EP0173552B1 (fr) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Composés recombinants d'ADN et l'expression de polypeptides comme le tPA |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB2197321B (en) | 1986-09-12 | 1990-10-03 | Genentech Inc | Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line |
DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
US5382425A (en) | 1992-01-13 | 1995-01-17 | Syntro Corporation | Recombinant swinepox virus |
FR2702373B1 (fr) | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
EP0668355B1 (fr) | 1993-12-20 | 1999-04-07 | Akzo Nobel N.V. | Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin |
FR2728795B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
FR2728794B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
EP0826063A1 (fr) | 1995-04-25 | 1998-03-04 | Vical Incorporated | Formulations en ampoule unidose de complexes adn/lipides |
DE69740033D1 (de) | 1996-07-03 | 2010-12-09 | Merial Inc | Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
ATE292980T1 (de) | 1996-10-11 | 2005-04-15 | Univ California | Immunostimulierende oligonucleotidekonjugate |
CZ300172B6 (cs) * | 1997-02-28 | 2009-03-04 | Acambis Inc. | Chimerický živý, infekcní, oslabený virus, lécivopro prevenci nebo lécbu flavivirových infekcí s jeho obsahem a molekula nukleové kyseliny jej kódující |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6294176B1 (en) | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
US6645740B1 (en) | 1999-06-10 | 2003-11-11 | Merial Limited | Nucleic acids encodings equine GM-CSF |
JP2003502345A (ja) | 1999-06-10 | 2003-01-21 | メリアル | ペットまたはスポ−ツ用動物のためのdnaワクチン |
FR2796397B1 (fr) | 1999-07-16 | 2006-09-01 | Merial Sas | Genes de calicivirus felin et vaccins notamment vaccins recombines |
-
2001
- 2001-04-06 FR FR0104737A patent/FR2823222B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-05 EP EP02759818.4A patent/EP1377660B1/fr not_active Expired - Lifetime
- 2002-04-05 SI SI200231069A patent/SI1377660T1/sl unknown
- 2002-04-05 BR BRPI0208896A patent/BRPI0208896B1/pt active IP Right Grant
- 2002-04-05 ES ES02759818.4T patent/ES2566044T3/es not_active Expired - Lifetime
- 2002-04-05 PL PL365210A patent/PL207584B1/pl unknown
- 2002-04-05 CA CA2448796A patent/CA2448796C/fr not_active Expired - Lifetime
- 2002-04-05 IL IL15820402A patent/IL158204A0/xx unknown
- 2002-04-05 PL PL391444A patent/PL210306B1/pl unknown
- 2002-04-05 WO PCT/FR2002/001200 patent/WO2002081621A2/fr active Search and Examination
- 2002-04-05 JP JP2002579985A patent/JP4426761B2/ja not_active Expired - Lifetime
- 2002-04-05 DK DK02759818.4T patent/DK1377660T3/en active
- 2002-04-05 ES ES15162832T patent/ES2767413T3/es not_active Expired - Lifetime
- 2002-04-05 RU RU2003132455/13A patent/RU2283138C2/ru active
- 2002-04-05 AU AU2002307971A patent/AU2002307971B2/en not_active Expired
- 2002-04-05 MX MXPA03008998A patent/MXPA03008998A/es active IP Right Grant
- 2002-04-05 EP EP15162832.8A patent/EP2979705B1/fr not_active Expired - Lifetime
- 2002-04-05 HU HU0401868A patent/HU230122B1/hu active Protection Beyond IP Right Term
-
2003
- 2003-09-30 ZA ZA2003/07620A patent/ZA200307620B/en unknown
- 2003-10-01 IL IL158204A patent/IL158204A/en active IP Right Grant
-
2004
- 2004-07-02 HK HK04104755.3A patent/HK1061868A1/zh not_active IP Right Cessation
- 2004-07-02 HK HK16106775.0A patent/HK1219412A1/zh not_active IP Right Cessation
-
2007
- 2007-08-14 IL IL185263A patent/IL185263A0/en active IP Right Grant
-
2015
- 2015-09-18 HU HUS1500047C patent/HUS1500047I1/hu unknown
-
2016
- 2016-04-06 CY CY20161100275T patent/CY1117676T1/el unknown
- 2016-04-19 FR FR16C0014C patent/FR16C0014I2/fr active Active
- 2016-04-20 NL NL300806C patent/NL300806I2/nl unknown
- 2016-04-20 LT LTPA2016011C patent/LTC1377660I2/lt unknown
- 2016-04-26 BE BE2016C021C patent/BE2016C021I2/fr unknown
- 2016-04-26 LU LU93048C patent/LU93048I2/fr unknown
- 2016-05-20 CY CY2016018C patent/CY2016018I2/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000012128A2 (fr) * | 1998-08-28 | 2000-03-09 | Hawaii Biotechnology Group, Inc. | Vaccin a sous-unite proteique non structurale recombinante contre les infections a flavivirus |
Non-Patent Citations (2)
Title |
---|
OCAZIONEZ JIMENEZ R ET AL: "Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 6, 8 November 2000 (2000-11-08), pages 648 - 654, XP004219903, ISSN: 0264-410X * |
WENGLER G ET AL: "AN ANALYSIS OF THE ANTIBODY RESPONSE AGAINST WEST NILE VIRUS E PROTEIN PURIFIED BY SDS-PAGE INDICATES THAT THIS PROTEIN DOES NOT CONTAIN SEQUENTIAL EPITOPES FOR EFFICIENT INDUCTION OF NEUTRALIZING ANTIBODIES", JOURNAL OF GENERAL VIROLOGY, vol. 70, no. 4, 1989, pages 987 - 992, XP001050460, ISSN: 0022-1317 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002081621A3 (fr) | Vaccin contre le virus de la fievre du nil | |
WO2009034315A3 (fr) | Vaccin | |
WO2003059381A3 (fr) | Préparations immunogènes et vaccins à base d'arn | |
DE69939747D1 (de) | Verfahren von dna-impfung | |
SG153874A1 (en) | Neutralizing epitope-based growth enhancing vaccine | |
WO2007024947A3 (fr) | Vaccins contre la grippe canine | |
GT200200139A (es) | Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales | |
UA110328C2 (en) | Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration | |
WO2005035558A3 (fr) | Antigenes de piscirickettsia salmonis et leur utilisation | |
EP1818406A4 (fr) | Construction genique, vecteur et vaccin a adn pour la vaccination d'animaux aquatiques | |
ES2190908T1 (es) | Composicion cosmetica que comprende seroalbumina humana obtenida de animales transgenicos no humanos. | |
WO2009077577A3 (fr) | Antigènes de vaccin provenant de la piscirickettsia salmonis | |
AR027926A1 (es) | Vacunas de adn mejoradas para animales de granja | |
DE602005011041D1 (de) | Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort | |
DE60239753D1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
AR019785A1 (es) | Pestivirus no diseminantes | |
WO2004058816A3 (fr) | Corps d'inclusion pour la vaccination orale d'animaux | |
DE60126490D1 (de) | Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form | |
WO2004058806A3 (fr) | Corps d'inclusion utilises comme antigenes dans la vaccination d'animaux | |
WO2004073604A3 (fr) | Vaccins adn exprimant une toxine adp-ribosyltransferase depourvue d'activite adp-ribosyltransferase | |
DK1027895T3 (da) | Erysipelothrix rhusiopathiae-antigener og vaccinepræparater | |
WO2002000250A3 (fr) | Vaccins hiv-1 et methodes de depistage correspondantes | |
DE60236943D1 (de) | Induzierte immunantwort gegen den katzen-immunschwäche-virus | |
AU2003287061A8 (en) | Ferritin light subunit variant-encoding nucleic acids, polypeptides, transgenic animals, antibodies, and methods of use thereof | |
Biuk-Rudan et al. | Specific and non-specific protection of pigs exposed to contact infection with Aujeszky's disease virus (ADV) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/07620 Country of ref document: ZA Ref document number: 200307620 Country of ref document: ZA Ref document number: 2448796 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 158204 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/008998 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002579985 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002307971 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002759818 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002759818 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 185263 Country of ref document: IL |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |